Arteriosclerosis - Pipeline Review, H1 2014
M2 - 52 mins ago
Research and Markets (http://www.researchandmarkets.com/research/64g45x/arteriosclerosis) has announced the addition of the "Arteriosclerosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arteriosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arteriosclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arteriosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arteriosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AnGes MG - Angelini - CytoTools - ECI - Johnson & Johnson - Kowa Company - KunWha Pharmaceutical - LTT Bio-Pharma - Nippon Shinyaku For more information visit http://www.researchandmarkets.com/research/64...osclerosis
Final Glance: Pharmaceuticals companies
AP - Tue Jun 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue Jun 24, 5:05PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Tue Jun 24, 12:17PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue Jun 24, 12:17PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Avon's Calling, but Will Higher Profits Push Investors to Open the Door?
at The Street - Tue Jun 24, 8:45AM CDT
The beauty products company has undergone a makeover with revamped leadership, and Avon might add a new look to your portfolio.
Jennifer Doudna, Ph.D., and Emmanuelle Charpentier, Ph.D., Win 2014 Dr. Paul Janssen Award for Biomedical Research
PR Newswire - Tue Jun 24, 8:30AM CDT
Johnson & Johnson today named Dr. Jennifer Doudna of the University of California at Berkeley and the Howard Hughes Medical Institute, and Dr. Emmanuelle Charpentier, of the Hannover Medical School and Helmholtz Centre for Infection Research (HZI), Germany and The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umea University, Sweden, the winners of the 2014 Dr. Paul Janssen Award for Biomedical Research. Their collaboration led to the discovery of a new method for precisely manipulating genetic information in ways that should produce new insights in health and disease, and may lead to the discovery of new targets for drug development.
Johnson & Johnson Innovation Announces Immuno-Oncology Lung Cancer Collaboration with the Dana-Farber Cancer Institute's Belfer Institute for Applied Cancer Science
PR Newswire - Tue Jun 24, 7:00AM CDT
Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. today announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Through the collaboration, Janssen scientists will work with the research team at Dana-Farber's Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen's lung cancer discovery pipeline.
Cost Controls vs. Curing Citizens: Fallout from the U.K.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Just like the protagonist in " Fortunately, Unfortunately " Gilead Sciences is experiencing a disproportionate amount of highs and lows. Fortunately, the big biotech released great phase 3 data out of Japan for an experimental hepatitis-c combo...
FIFA World Cup: China Scores over Brazil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 3:45PM CDT
China will earn significantly from the costliest FIFA World Cup tournament ever; that too without making massive investments.
Stryker Momentum Continues but M&A Activities Pose Threat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 1:50PM CDT
Investors are confident about Stryker Corporation (SYK) given its continued momentum based on its potential to become a medtech company.
Stock Market News for June 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 9:06AM CDT
Benchmarks closed Friday’s trading session with modest gains as optimism from Wednesday’s policy statement spilled over into a second successive day
The Zacks Analyst Blog Highlights: Intel, Boeing, Chevron, Johnson & Johnson and Vertex Pharmaceuticals
PR Newswire - Mon Jun 23, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Intel Corporation (Nasdaq:INTC-Free Report), Boeing Co. (NYSE:BA-Free Report), Chevron Corp. (NYSE:CVX-Free Report), Johnson & Johnson (NYSE:JNJ-Free Report) and Vertex Pharmaceuticals Inc. (Nasdaq:VRTX-Free Report).
Johnson & Johnson Has Returned 16.4% Since SmarTrend Recommendation (JNJ)
Comtex SmarTrend(R) - Fri Jun 20, 5:07PM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 4 months, Johnson & Johnson has returned 16.40% as of today's recent price of $105.27.
Tetraphase Progresses with Eravacycline Late-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 4:20PM CDT
Tetraphase Pharmaceuticals (TTPH) announced the completion of patient enrolment for the phase III IGNITE 2 study on eravacycline.
SmarTrend Watching for Potential Pullback in Shares of Johnson & Johnson After 1.41% Gain
Comtex SmarTrend(R) - Fri Jun 20, 3:41PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $104.07 to a high of $105.48. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $103.87 on volume of 12.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.